Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Ionis and Roche agree on dry AMD treatment deal

Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.

Read More »

HIV Treatments That Could Make Redfield’s Prediction a Reality to Defeat AIDS Epidemic

Dr. Robert Redfield, the new head of the U.S. Centers for Disease Control and Prevention, boldly predicted in April 2018 that the AIDS epidemic can be defeated by 2025. Merck, Janssen and Gilead Sciences all released clinical data for HIV treatments that could make Redfield’s prediction a reality.

Read More »

J&J, Arrowhead reach gene-silencing drug deal

J&J agreed to develop and market Arrowhead Pharmaceuticals Inc.’s gene-silencing hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion.

Read More »

One Drop’s Apple Watch App Points to Trend in Wearable Health Devices

Personalized medicine continues to grow in importance, and having the ability to monitor health data has proven to be a significant desire for people as the number of wearable devices continues to grow.

Read More »

Supernus Pharma to Buy Biscayne Neurotherapeutics in Potential $183 Million Deal

Rockville, Maryland-based Supernus Pharmaceuticals is acquiring Biscayne Neurotherapeutics, which is located in Miami.

Read More »

Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, Pfizer

Checkmate Pharmaceuticals announced a clinical trial collaboration and supply agreement with the alliance between Merck KGaA and Pfizer Inc. to evaluate the TLR9 agonist CMP-001 in combination with the human anti-PD-L1 antibodyavelumab.

Read More »

FDA Clears SPR Therapeutics’ Non-Opioid Neurostimulation Pain Therapies

The U.S. Food and Drug Administration cleared Cleveland-based SPR Therapeutics’ SPRING endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation Systems for controlling pain.

Read More »

Novo Nordisk’s Semaglutide Hits Mark in T2D Trial

Novo Nordisk revealed that oral semaglutide achieved positive results in the PIONEER 5 study for the reduction of blood sugar levels and weight in adults with type 2 diabetes.

Read More »

Japan’s Eisai sets price tag of about $16,000 on liver cancer drug

Japan’s Eisai Co. Ltd. will price the company’s cancer drug Lenvima at about $16,000 for a month’s supply before discounts, after the U.S. Food and Drug Administration approved the product’s use in patients with a common form of liver cancer.

Read More »

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics set an average price of $315,000 per year for the company’s newly approved Fabry disease treatment.

Read More »

DEA Moving Forward With Reclassification of CBD Ahead of GW’s Launch of Epidiolex

The U.S. Drug Enforcement Agency is readdressing cannabis following the regulatory approval of the first cannabinoid-based drug for the treatment of some epilepsy patients.

Read More »

Alkermes Scores FDA Approval for Potential Game-Changing Schizophrenia Treatment

The U.S. FDA approved Alkermes plc’s Aristada Initio (aripiprazole lauroxil) as part of a combination treatment for schizophrenia.

Read More »

Adamis Pharma Sells Epinephrine Injector Rights to Novartis

Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.

Read More »

U.S. Food and Drug Administration Clears Wearable Device to Treat Opioid Addiction

DyAnsys Inc. announced that the U.S. Food and Drug Administration cleared the company’s auricular neurostimulation device, Drug Relief, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics.

Read More »

FDA approves lower dose of Lilly-Incyte arthritis drug

The U.S. Food and Drug Administration approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte, but declined to approve its higher and more lucrative dose.

Read More »

Newest Generation Of Leading Heart Stent Approved In U.S. For People With Coronary Artery Disease

Abbott received approval from the U.S. Food and Drug Administration for XIENCE Sierra, the newest generation of the gold-standard XIENCE everolimus-eluting coronary stent system.

Read More »

Lilly’s Taltz Receives First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving Genital Area

Eli Lilly and Company announced that the U.S. Food and Drug Administration approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area.

Read More »

FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems

The U.S. Food and Drug Administration permitted marketing of the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes.

Read More »

Roche wins UK watchdog’s nod for lymphoma drug

Britain’s healthcare watchdog NICE recommended Roche’s medicine Gazyvaro for previously untreated advanced follicular lymphoma patients after initially rejecting the medicine in 2017.

Read More »

Novartis Receives FDA Approval for Cosentyx Label Update to Include Moderate to Severe Scalp Psoriasis

Novartis announced that the U.S. Food and Drug Administration approved a label update for Cosentyx (secukinumab), the first interleukin-17A antagonist cleared to treat moderate to severe plaque psoriasis, to include data in moderate to severe scalp psoriasis.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom